332 related articles for article (PubMed ID: 26347001)
1. Anti-JC virus seroprevalence in a Finnish MS cohort.
Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
[TBL] [Abstract][Full Text] [Related]
2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
3. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
4. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Outteryck O; Zéphir H; Salleron J; Ongagna JC; Etxeberria A; Collongues N; Lacour A; Fleury MC; Blanc F; Giroux M; de Seze J; Vermersch P
Mult Scler; 2014 Jun; 20(7):822-9. PubMed ID: 24072722
[TBL] [Abstract][Full Text] [Related]
5. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
6. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
[TBL] [Abstract][Full Text] [Related]
7. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.
Outteryck O; Ongagna JC; Duhamel A; Zéphir H; Collongues N; Lacour A; Fleury MC; Berteloot AS; Blanc F; Giroux M; Vermersch P; de Sèze J
J Neurol; 2012 Nov; 259(11):2293-8. PubMed ID: 22527227
[TBL] [Abstract][Full Text] [Related]
8. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
Bozic C; Subramanyam M; Richman S; Plavina T; Zhang A; Ticho B
Eur J Neurol; 2014 Feb; 21(2):299-304. PubMed ID: 24894998
[TBL] [Abstract][Full Text] [Related]
9. Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.
Hegen H; Auer M; Bsteh G; Di Pauli F; Plavina T; Walde J; Deisenhammer F; Berger T
PLoS One; 2017; 12(3):e0174005. PubMed ID: 28319193
[TBL] [Abstract][Full Text] [Related]
10. Anti-JC virus antibody titres increase over time with natalizumab treatment.
Raffel J; Gafson AR; Malik O; Nicholas R
Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
[TBL] [Abstract][Full Text] [Related]
11. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
12. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
14. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time.
Peters J; Williamson E
J Neurol; 2017 Dec; 264(12):2409-2412. PubMed ID: 29034436
[TBL] [Abstract][Full Text] [Related]
17. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
18. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
[TBL] [Abstract][Full Text] [Related]
19. Smoking is not associated with higher prevalence of JC virus in MS patients.
Auer M; Bsteh G; Hegen H; Di Pauli F; Wurth S; Berger T; Deisenhammer F
Eur J Clin Microbiol Infect Dis; 2018 May; 37(5):907-910. PubMed ID: 29423619
[TBL] [Abstract][Full Text] [Related]
20. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]